Hubbry Logo
MethocarbamolMethocarbamolMain
Open search
Methocarbamol
Community hub
Methocarbamol
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Methocarbamol
Methocarbamol
Methocarbamol
View on Wikipedia
from Wikipedia

Methocarbamol
Clinical data
Trade namesRobaxin, Marbaxin, others
AHFS/Drugs.comMonograph
MedlinePlusa682579
License data
Pregnancy
category
  • AU: B2
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver
Elimination half-life1.14–1.24 hours[2]
Identifiers
  • (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.007.751 Edit this at Wikidata
Chemical and physical data
FormulaC11H15NO5
Molar mass241.243 g·mol−1
3D model (JSmol)
  • O=C(OCC(O)COc1ccccc1OC)N
  • InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14) checkY
  • Key:GNXFOGHNGIVQEH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain.[3][4] It may be used together with rest, physical therapy, and pain medication.[3][5][6] It has limited use for rheumatoid arthritis and cerebral palsy.[3][7] Effects generally begin within half an hour.[3] It is taken by mouth or injection into a vein.[3]

Common side effects include headaches, sleepiness, and dizziness.[3][8] Serious side effects may include anaphylaxis, liver problems, confusion, and seizures.[4] Use is not recommended in pregnancy and breastfeeding.[3][4] Because of the risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients.[3] Methocarbamol is a centrally acting muscle relaxant.[3] How it works is unclear, but it does not appear to affect muscles directly.[3]

Methocarbamol was developed in 1956 in the laboratories of A. H. Robins (later acquired by Pfizer). Studies were directed towards the development of propanediol derivatives which possessed muscle relaxant properties superior to those of mephenesin, which had low potency and a short duration of action.[9] It was approved for medical use in the United States in 1957.[3] It is available as a generic medication.[3][4] In 2023, it was the 121st most commonly prescribed medication in the United States, with more than 5 million prescriptions.[10][11] Methocarbamol is available in a fixed-dose combination with ibuprofen as methocarbamol/ibuprofen (sold under the brand name Summit Ultra).[12]

Medical use

[edit]

Methocarbamol is a muscle relaxant used to treat acute, painful musculoskeletal spasms in a variety of musculoskeletal conditions.[13] However, there is limited and inconsistent published research on the medication's efficacy and safety in treating musculoskeletal conditions, primarily neck and back pain.[13]

Methocarbamol injection may have a beneficial effect in the control of the neuromuscular spasms of tetanus.[6] It does not, however, replace the current treatment regimen.[6]

It is not useful in chronic neurological disorders, such as cerebral palsy or other dyskinesias.[3]

Currently, there is some suggestion that muscle relaxants may improve the symptoms of rheumatoid arthritis; however, there is insufficient data to prove its effectiveness or to answer concerns regarding optimal dosing, choice of muscle relaxant, adverse effects, and functional status.[7]

Comparison to similar agents

[edit]

The clinical effectiveness of methocarbamol compared to other muscle relaxants is not well known.[13] One trial of methocarbamol versus cyclobenzaprine, a well-studied muscle relaxant, in those with localized muscle spasm found there were no significant differences in their effects on muscle spasm, limitation of motion, or limitation of daily activities.[13]

Contraindications

[edit]

Contraindications for methocarbamol include:

Side effects

[edit]

Methocarbamol is a centrally acting skeletal muscle relaxant that has significant potential adverse effects, especially on the central nervous system.[3]

Potential side effects of methocarbamol include:

  • Most commonly drowsiness, blurred vision, headache, nausea, and skin rash.[8]
  • Possible clumsiness (ataxia), upset stomach, flushing, mood changes, trouble urinating, itchiness, and fever.[14][15]
  • Both tachycardia (fast heart rate) and bradycardia (slow heart rate) have been reported.[15]
  • Hypersensitivity reactions and anaphylatic reactions are also reported.[5][6]
  • May cause respiratory depression when combined with benzodiazepines, barbiturates, codeine, or other muscle relaxants.[16]
  • May cause urine to turn black, blue, or green.[14]

While the product label states that methocarbamol can cause jaundice, there is minimal evidence to suggest that methocarbamol causes liver damage.[8] During clinical trials of methocarbamol, there were no laboratory measurements of liver damage indicators, such as serum transaminase (AST/ALT) levels, to confirm hepatotoxicity.[8] Although unlikely, it is impossible to rule out that methocarbamol may cause mild liver injury with use.[8]

Elderly

[edit]

Skeletal muscle relaxants are associated with an increased risk of injury among older adults.[17] Methocarbamol appeared to be less sedating than other muscle relaxants, most notably cyclobenzaprine but had a similarly increased risk of injury.[16][17] Methocarbamol is cited along with "most muscle relaxants" in the 2012 Beers Criteria as being "poorly tolerated by older adults, because of anticholinergic adverse effects, sedation, increased risk of fractures," noting that "effectiveness dosages tolerated by older adults is questionable."[18]

Pregnancy

[edit]

Methocarbamol is labeled by the FDA as a pregnancy category C medication.[6] The teratogenic effects of the medication are not known and should be given to pregnant women only when indicated.[6]

Overdose

[edit]

There is limited information available on the acute toxicity of methocarbamol.[5][6] Overdose is observed frequently in conjunction with CNS depressants such as alcohol or benzodiazepines and will have symptoms of nausea, drowsiness, blurred vision, hypotension, seizures, and coma.[6] There are reported deaths with an overdose of methocarbamol alone or in the presence of other CNS depressants.[5][6]

Abuse

[edit]

Unlike other carbamates such as meprobamate and its prodrug carisoprodol, methocarbamol has greatly reduced abuse potential.[19] Studies comparing it to the benzodiazepine lorazepam and the antihistamine diphenhydramine, along with placebo, find that methocarbamol produces increased "liking" responses and some sedative-like effects; however, at higher doses dysphoria is reported.[19] It is considered to have an abuse profile similar to, but weaker than, lorazepam.[19]

Interactions

[edit]

Methocarbamol may inhibit the effects of pyridostigmine bromide.[5][6] Therefore, methocarbamol should be used with caution in those with myasthenia gravis taking anticholinesterase medications.[6]

Methocarbamol may disrupt certain screening tests as it can cause color interference in laboratory tests for 5-hydroxy-indoleacetic acid (5-HIAA) and in urinary testing for vanillylmandelic acid (VMA) using the Gitlow method.[6]

Pharmacology

[edit]

Mechanism of action

[edit]

The mechanism of action of methocarbamol has not currently been established.[3] Its effect is thought to be localized to the central nervous system rather than a direct effect on skeletal muscles.[3] It does not affect the motor end plate or the peripheral nerve fiber.[6] The efficacy of the medication is likely related to its sedative effect.[3] Alternatively, methocarbamol may act via inhibition of acetylcholinesterase, similarly to carbamate.[20]

Pharmacokinetics

[edit]

In healthy individuals, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg.[6] The mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.[6] The elimination half-life was longer in the elderly, those with kidney problems, and those with liver problems.[6]

Metabolism

[edit]

Methocarbamol is the carbamate derivative of guaifenesin, but does not produce guaifenesin as a metabolite, because the carbamate bond is not hydrolyzed metabolically;[8][6] its metabolism is by Phase I ring hydroxylation and O-demethylation, followed by Phase II conjugation.[6] All the major metabolites are unhydrolyzed carbamates.[21][22] Small amounts of unchanged methocarbamol are also excreted in the urine.[5][6]

Society and culture

[edit]

Methocarbamol was approved as a muscle relaxant for acute, painful musculoskeletal conditions in the United States in 1957.[8] Muscle relaxants are widely used to treat low back pain, one of the most frequent health problems in industrialized countries. Currently, there are more than 3 million prescriptions filled yearly.[8] Methocarbamol and orphenadrine are each used in more than 250,000 U.S. emergency department visits for lower back pain each year.[23] In the United States, low back pain is the fifth most common reason for all physician visits and the second most common symptomatic reason.[24] In 80% of primary care visits for low back pain, at least one medication was prescribed at the initial office visit and more than one third were prescribed two or more medications.[25] The most commonly prescribed drugs for low back pain included skeletal muscle relaxants.[26] Cyclobenzaprine and methocarbamol are on the U.S. Medicare formulary, which may account for the higher use of these products.[17]

Economics

[edit]

It is relatively inexpensive as of 2016.[27] The generic formulation of the medication is relatively inexpensive, costing less than the alternative metaxalone in 2016.[28][27]

Marketing

[edit]
Generic methocarbamol 750mg tablet.

Methocarbamol without other ingredients is sold under the brand name Robaxin in the U.K., U.S., Canada[29] and South Africa; it is marketed as Lumirelax in France, Ortoton in Germany and many other names worldwide.[30] In combination with other active ingredients it is sold under other names: with acetaminophen (paracetamol), under trade names Robaxacet and Tylenol Body Pain Night; with ibuprofen as Robax Platinum; with acetylsalicylic acid as Robaxisal in the U.S. and Canada.[31][32] However, in Spain the tradename Robaxisal is used for the paracetamol combination instead of Robaxacet.[citation needed] These combinations are also available from independent manufacturers under generic names.[citation needed]

Research

[edit]

Although opioids are typically first-line treatments in severe pain, several trials suggest that methocarbamol may improve recovery and decrease hospital length of stay in those with muscle spasms associated with rib fractures.[33][34][35] However, methocarbamol was less useful in the treatment of acute traumatic pain in general.[36]

Long-term studies evaluating the risk of development of cancer in using methocarbamol have not been performed.[5][6] There are currently no studies evaluating the effect of methocarbamol on mutagenesis or fertility.[5][6]

The safety and efficacy of methocarbamol have not been established in pediatric individuals below the age of 16 except in tetanus.[5][6]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Methocarbamol

View on Grokipedia
from Grokipedia
Methocarbamol is a centrally relaxant primarily used as an adjunct to rest, , and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Approved by the FDA in 1957, it is available in oral tablet form (typically 500 mg or 750 mg), oral suspension (approved 2025), and injectable formulations for intravenous or intramuscular administration, and is often combined with analgesics like acetaminophen or ibuprofen for enhanced . Chemically, it is a derivative of guaifenesin with the molecular formula C₁₁H₁₅NO₅, acting without directly affecting skeletal muscle contractility. The exact of methocarbamol in humans remains unknown, though it is believed to involve general (CNS) depression, potentially by inhibiting the reticular activating system or blocking spinal polysynaptic reflexes, which reduces nerve transmission in the and prolongs the refractory period of muscle cells. Pharmacologically, it is rapidly absorbed after with an within 30 minutes and peak plasma concentrations at about 2 hours; it exhibits moderate (46-50%) and is metabolized in the liver via dealkylation, , and conjugation, with a of 1-2 hours and primary as inactive metabolites in the . In addition to its FDA-approved indications for muscle spasms and (injectable), off-label uses include management of . Common adverse effects include , , , and , while more serious reactions such as seizures, , or may occur, particularly with rapid intravenous administration. Contraindications encompass known to the drug, intravenous use in patients with renal impairment due to the vehicle , and caution in those with or concurrent use of CNS depressants like alcohol. Standard adult dosing starts at 1.5 g orally four times daily for the first 48-72 hours, reducing to 4-6 g daily thereafter, with a maximum of 8 g per day initially; injectable doses are limited to 3 g per day for no more than three days to minimize risks like .

Medical uses

Indications

Methocarbamol is primarily indicated as an adjunct to rest, , and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions, including muscle spasms due to strains, sprains, or injuries. This use targets short-term symptoms rather than underlying structural issues, with the medication's properties contributing to spasm relief without directly relaxing skeletal muscles. In the context of acute , methocarbamol is supported by clinical guidelines from the , which recommend relaxants as a pharmacologic option alongside nonsteroidal anti-inflammatory drugs when nonpharmacologic therapies are insufficient, based on moderate-quality evidence showing modest short-term benefits. A 2024 confirms that methocarbamol, when combined with NSAIDs such as indomethacin or naproxen, improves pain outcomes after one week of use. Methocarbamol injection is also indicated as an adjunct in the management of to control localized or generalized muscle spasms, typically combined with other supportive therapies such as antibiotics and wound care. The medication is intended for short-term administration, generally limited to 48 to 72 hours initially, to minimize risks associated with prolonged use while integrating it into a broader treatment plan that emphasizes recovery and rehabilitation. Methocarbamol is not indicated for chronic spasticity or rigidity stemming from neurological disorders, such as or , where it has demonstrated limited efficacy.

Administration and dosage

Methocarbamol is primarily administered orally in tablet form, with available strengths of 500 mg and 750 mg. For adults, the initial oral dosage is 1,500 mg (three 500 mg tablets or two 750 mg tablets) taken four times daily for the first 48 to 72 hours, totaling up to 6,000 mg per day; in severe cases, up to 8,000 mg per day may be used initially. Maintenance therapy typically involves 4,000 to 4,500 mg per day in divided doses, such as 1,000 mg four times daily, with adjustments based on clinical response. Intravenous (IV) or intramuscular (IM) administration is reserved for severe cases or when oral therapy is not feasible, using a 10% injectable solution. The usual adult dose is 1 g IV or every 8 hours, not exceeding 3 g per day, with IV infusions diluted in no less than 250 mL of fluid and administered slowly (at a rate not exceeding 300 mg per minute) to minimize risks like or . It is not intended for subcutaneous injection, and total daily dosage should not exceed 3 g for more than 3 consecutive days except in treatment. Dosage adjustments are recommended for patients with severe renal or hepatic impairment due to prolonged and potential accumulation; a 50% dose reduction may be necessary, with close monitoring, while the IV formulation is contraindicated in renal impairment owing to the . Therapy with methocarbamol is intended for short-term use only, typically up to 1 week for musculoskeletal conditions, after which doses should be tapered if longer treatment is required to assess ongoing need and minimize risks. For pediatric patients with , the initial IV dose is 15 mg/kg or 500 mg/m², repeated every 6 hours as needed, not exceeding 1.8 g/m² per day for more than 3 days.

Comparison with other muscle relaxants

Methocarbamol is associated with less than , with sedation occurring in 31% of patients receiving methocarbamol compared to 58% with cyclobenzaprine in head-to-head trials, while both agents show similar short-term efficacy for acute when combined with nonsteroidal anti-inflammatory drugs. A and of randomized controlled trials indicates that non-benzodiazepine antispasmodics, including methocarbamol and , provide small reductions in pain intensity at up to two weeks compared to , though evidence certainty is very low and improvements in disability are not significant. Compared to , methocarbamol has a faster following oral administration, typically within 30 minutes and peaking at 1 to 2 hours, versus 's onset of 1 to 2 hours and peak at 2 to 3 hours. However, unlike , which is effective for in neurological conditions such as due to its action on GABA-B receptors at the spinal level, methocarbamol lacks substantial antispastic effects and is primarily indicated for acute musculoskeletal conditions. Methocarbamol demonstrates lower abuse potential than , as it is not a and animal studies show minimal reinforcing effects relative to benzodiazepines or barbiturates, whereas is classified as a Schedule IV due to its metabolite meprobamate's sedative properties. It is often preferred in outpatient settings over because of fewer effects, such as dry mouth and blurred vision, which are prominent with due to its diphenhydramine-like structure. Randomized controlled trials reveal that methocarbamol shows no superiority over for pain relief in chronic beyond three weeks, with mean differences in pain scores of 0.6 on a 100-point scale (95% CI -4.5 to 5.7). Nonetheless, it offers better tolerability than , as it is not associated with dependency risks and causes fewer adverse events in settings for acute . In terms of cost-effectiveness, generic methocarbamol is substantially cheaper than branded alternatives like Soma (), with a 60-tablet supply of 750 mg methocarbamol costing approximately $25 out-of-pocket compared to higher prices for Soma despite available generics for .

Contraindications and special populations

Contraindications

Methocarbamol is contraindicated in patients with known to the drug or any of its excipients, as this can lead to severe allergic reactions including . The intravenous formulation is specifically contraindicated in patients with impaired renal function, due to the presence of polyethylene glycol 300 as an excipient, which carries a risk of metabolic acidosis, renal injury, and hyperosmolarity. For oral administration, severe renal impairment (such as creatinine clearance below 30 mL/min) requires careful consideration, as unmetabolized drug may accumulate, though it is not an absolute contraindication. Methocarbamol should be avoided or used with extreme caution in patients with a history of seizures, as the drug may lower the , particularly with intravenous use in those with . In individuals with , especially those receiving anticholinesterase agents like , methocarbamol is relatively contraindicated without close monitoring, as it may inhibit the effects of these agents and exacerbate . Active liver disease warrants caution rather than absolute avoidance, given reports of rare and reduced clearance in , but no specific is established. Similarly, while not formally contraindicated, methocarbamol should be used judiciously in comatose or pre-comatose states due to its central nervous system depressant effects, which could worsen or respiratory depression when combined with other CNS depressants. Methocarbamol has no specific warnings from the FDA, though prescribing guidelines emphasize screening for reactions prior to initiation to mitigate risks. The aligns with similar precautions, prioritizing allergy history assessment in product information for authorized formulations.

Use in elderly

Methocarbamol use in elderly patients aged 65 and older warrants caution due to age-related pharmacokinetic changes, including slightly prolonged and reduced clearance, particularly in those with common renal impairment. These alterations can heighten and , increasing the risk of falls and injuries. The American Geriatrics Society recommends avoiding methocarbamol in older adults because of its association with , anticholinergic effects, and elevated fracture risk, with an absolute risk increase of approximately 0.2% for injuries. To mitigate risks, initiate therapy at lower doses, such as 500 mg every 8 hours, representing about half the standard adult maintenance dose, with gradual based on response and tolerability. Elderly patients experience a higher incidence of and drowsiness compared to younger adults, which can lead to accidents; for instance, use of methocarbamol is linked to a 1.42-fold increased of events like falls or fractures. Limit use to short-term (typically 2-3 days for acute musculoskeletal conditions) to minimize accumulation and adverse effects. Monitoring is essential, including regular assessment for , anticholinergic-like symptoms (e.g., dry mouth, ), and balance issues, especially in frail individuals. is a concern in this population, as methocarbamol is frequently co-prescribed with opioids or other CNS depressants, amplifying sedation and respiratory risks; clinicians should evaluate concurrent medications and prioritize non-pharmacologic alternatives like when possible. Drowsiness, a common , is notably amplified in the elderly due to slower drug clearance.

Use in pregnancy and lactation

Methocarbamol is classified as FDA Pregnancy Category C, indicating that animal reproduction studies have not been conducted and it is not known whether the drug can cause fetal harm when administered to pregnant women or affect reproductive capacity. There have been rare reports of fetal and congenital abnormalities, such as contractures, following in utero exposure to methocarbamol, though causality has not been established. Limited human data exist, with one retrospective analysis of National Poison Data System records showing no association between methocarbamol exposure during pregnancy and major congenital malformations or other adverse outcomes. Due to these uncertainties, methocarbamol should be used during pregnancy only if the potential benefits justify the possible risks to the fetus, particularly for acute muscle spasms where non-pharmacologic alternatives are insufficient. In the third trimester, additional caution is advised because methocarbamol crosses the and may cause neonatal if used near delivery. Its rapid metabolism and clearance may limit prolonged fetal exposure. Regarding , no published data are available on the levels of methocarbamol in , but the drug and its metabolites are known to be excreted in the milk of dogs, suggesting possible transfer in humans. The amount is likely low given its molecular weight and metabolism. No adverse effects in breastfed infants have been reported, though caution is advised as the presence in human milk is unknown. Infants should be monitored for , poor feeding, and inadequate if the drug is used during . Non-drug therapies are preferred for muscle spasms in lactating women unless severe symptoms warrant use.

Adverse effects

Common side effects

Methocarbamol commonly causes mild to moderate adverse reactions, primarily affecting the , with drowsiness and being the most frequent, occurring in a dose-dependent manner. These effects are attributed to the drug's CNS-depressant properties. In a randomized, double-blind, -controlled evaluating methocarbamol for acute , adverse events were reported in 19% of patients receiving methocarbamol (versus 17% on ), predominantly consisting of and . Dizziness and lightheadedness are also prevalent, often emerging shortly after administration and contributing to impaired coordination or balance. Headache and nausea occur at lower but notable rates, typically resolving without intervention. Blurred vision or diplopia may arise transiently in some users, though less commonly. Data from post-marketing surveillance and early clinical studies indicate that these effects generally manifest within the first dose and subside upon discontinuation of the medication. In long-term use studies for , adverse effects including drowsiness and were observed in approximately 10% of patients on methocarbamol, with no serious events documented. These side effects are more pronounced in the elderly due to age-related changes in , but they remain self-limiting in most cases.

Serious side effects

Serious side effects of methocarbamol, though rare, can be life-threatening and necessitate prompt medical intervention. reactions, including and , have been reported, manifesting as , swelling of the face or throat, and difficulty breathing; these carry a risk of fatality. Such reactions are linked to known contraindications in patients with prior to the drug. Seizures represent another severe adverse effect, occurring rarely and primarily during intravenous administration in individuals predisposed due to a history of or disorders. Case reports, including those documented after 2020, highlight this risk in vulnerable populations, underscoring the need for caution in such patients. Hepatic toxicity is uncommon, with rare instances of cholestatic noted in post-marketing . Long-term use warrants monitoring of , particularly in patients with underlying hepatic impairment, as metabolism occurs primarily in the liver. Central nervous system disturbances, such as confusion and hallucinations, arise infrequently at therapeutic doses, though these effects intensify in overdose scenarios. Cardiovascular events like have been observed, especially with intravenous formulations, as reported in postmarketing experience.

Overdose

Methocarbamol overdose typically presents with , including profound sedation, , , , and . In severe cases, particularly with massive ingestions exceeding 10 grams, symptoms can progress to , respiratory depression, , and seizures. Isolated methocarbamol overdose is uncommon and rarely life-threatening without concomitant use of alcohol or other depressants, which can exacerbate toxicity. Management of methocarbamol overdose is entirely supportive, as no specific antidote exists. Initial interventions include gastrointestinal decontamination with activated charcoal if ingestion was recent and the patient is alert, followed by monitoring and maintenance of vital signs, airway patency, and urinary output. For respiratory failure or severe hypotension, intubation and mechanical ventilation may be required, along with intravenous fluids and vasopressors as needed. Due to methocarbamol's rapid absorption, prompt intervention is critical to mitigate peak effects. The (LD50) of methocarbamol in animal models ranges from 1,000 to 2,000 mg/kg orally, varying by species (e.g., 1,320 mg/kg in rats, 2,000 mg/kg in dogs). In humans, overdose is rarely fatal with timely supportive care; for instance, adults have survived ingestions of 22-30 grams with primarily extreme drowsiness and full recovery after . is ineffective for enhancing elimination due to methocarbamol's moderate of approximately 50%.

Abuse potential

Methocarbamol exhibits low abuse potential and is not classified as a by the U.S. (DEA), in contrast to , which is scheduled as a Schedule IV drug due to its higher risk of misuse and dependence. is rare with methocarbamol, unlike with , which can produce and euphoric effects more readily. A double-blind study involving 14 adult males with histories of abuse evaluated oral methocarbamol at doses of 2.25 g, 4.5 g, and 9 g, compared to (1 mg, 2 mg, 4 mg) and . Methocarbamol produced dose-related increases in subjective ratings of drug liking and effects, but these were accompanied by significant and side effects at higher doses, reducing its overall attractiveness for . In comparison, elicited stronger reinforcing effects without comparable , indicating methocarbamol's abuse liability is lower than that of benzodiazepines like . Misuse of methocarbamol typically involves recreational ingestion of high doses, ranging from 200 mg to 500 mg or more, often combined with alcohol to enhance , though such patterns are uncommon. The drug's properties, a common , can drive this misuse in individuals seeking relaxation or intoxication. Dependence on methocarbamol is minimal, with no evidence of significant tolerance development in clinical studies; chronic use may lead to mild , manifesting as anxiety or irritability upon discontinuation, but physical withdrawal symptoms are not prominent. According to the 2024 National Survey on Drug Use and Health by the Substance Abuse and Mental Health Services Administration (SAMHSA), misuse of prescription tranquilizers or sedatives, which includes muscle relaxants like methocarbamol, affected 1.6% of individuals aged 12 or older (approximately 4.6 million people) in the past year, with no significant change from prior years; methocarbamol contributes minimally to this figure given its low abuse potential. Methocarbamol is not recommended for patients with a history of substance use disorder due to the potential for enhanced CNS depression when combined with alcohol or other sedatives.

Drug interactions

Pharmacokinetic interactions

Methocarbamol demonstrates limited pharmacokinetic interactions with other medications, primarily owing to its metabolism via non-specific hepatic pathways involving dealkylation and , without well-characterized involvement of major (CYP) enzymes. This reduces the risk of significant metabolism-based drug-drug interactions compared to agents reliant on specific CYP isoforms. Regarding absorption, no substantial delays or alterations have been documented with concurrent use of antacids or other gastrointestinal modifiers, as methocarbamol is rapidly and nearly completely absorbed from the oral route regardless of food intake. Distribution interactions are also minimal; methocarbamol is approximately 46-50% bound to plasma proteins, limiting the potential for clinically relevant displacement of highly protein-bound drugs such as , though routine monitoring of international normalized ratio (INR) is advised during coadministration to detect any unexpected changes. Pharmacokinetic studies indicate no major interactions mediated by (P-gp) transport, with methocarbamol showing negligible substrate or inhibitor activity at this efflux transporter. Excretion pathways, involving renal clearance of metabolites as and conjugates, similarly lack reported modifiers that significantly alter elimination rates. Overall, these characteristics contribute to methocarbamol's favorable profile for , with clinicians advised to monitor for subtle changes in exposure during .

Pharmacodynamic interactions

Methocarbamol exerts (CNS) depressant effects, which can lead to additive pharmacodynamic interactions with other CNS depressants, including alcohol, opioids, and benzodiazepines. These combinations may intensify , , and impairment of mental and physical abilities, while also elevating the risk of respiratory depression and profound CNS inhibition. For instance, concurrent use with opioids has been associated with increased adverse events due to synergistic properties, necessitating careful monitoring or avoidance to prevent life-threatening outcomes. Methocarbamol possesses mild activity, which can synergize with other medications to exacerbate effects such as dry mouth, , , and , particularly in vulnerable populations like the elderly. This interaction arises from the shared blockade of muscarinic receptors, amplifying peripheral and central anticholinergic burden. Caution is advised when combining methocarbamol with agents like certain antihistamines or antidepressants, as this may heighten the risk of or . The hypotensive potential of methocarbamol can be potentiated through pharmacodynamic with antihypertensive agents, particularly those involving alpha-adrenergic blockade or , leading to enhanced lowering and increased risk of . This additive effect stems from methocarbamol's own capacity to induce and mild alpha-blocking-like activity in the vasculature. Patients on antihypertensives should be monitored for symptoms of excessive , such as or syncope, during coadministration. Methocarbamol has no known significant pharmacokinetic or pharmacodynamic interactions with ibuprofen (Advil) or other nonsteroidal anti-inflammatory drugs (NSAIDs) and is generally safe to combine for the management of muscle pain and inflammation, with combination products available in some markets. However, individual factors such as medical history, dosage, concurrent medications, kidney function, gastrointestinal risks, and cardiovascular considerations should be evaluated, and consultation with a healthcare professional is recommended. There is no documented drug interaction between indomethacin and methocarbamol that causes orthostatic hypotension or syncope. These drugs are sometimes combined (e.g., in products like Ardosons or in clinical studies) for enhanced pain relief without reported adverse effects related to blood pressure drops or fainting. While methocarbamol may rarely cause hypotension (especially with IV administration) and indomethacin can affect blood pressure (including occasional use to treat orthostatic hypotension), no synergistic interaction leading to orthostatic hypotension or syncope is reported in reliable sources. Methocarbamol can interfere with certain laboratory tests, producing false-positive results for urinary (5-HIAA) when using the nitrosonaphthol reagent and for (VMA) via the Gitlow method, due to chemical . Clinicians should inform patients of this interference to avoid misdiagnosis of conditions like or . Guidelines recommend avoiding methocarbamol in patients taking monoamine oxidase inhibitors (MAOIs) owing to the potential for hypertensive crisis, although specific mechanistic data for this combination remain limited; this precaution aligns with broader warnings for CNS-active agents that may indirectly influence catecholamine dynamics.

Pharmacology

Mechanism of action

Methocarbamol is a centrally acting skeletal muscle relaxant whose precise mechanism of action has not been fully established. It primarily exerts its effects through general central nervous system (CNS) depression, without directly influencing skeletal muscle contractility, motor end plates, or nerve fibers. The drug inhibits polysynaptic reflexes in the and , reducing muscle hyperactivity by depressing interneuronal transmission in polysynaptic pathways and suppressing multisynaptic pathways. This action decreases nerve impulses at subcortical levels, including the and , leading to lowered . Methocarbamol does not significantly affect monosynaptic reflexes or the , distinguishing its central mode of action. Preclinical studies in animal models demonstrate that methocarbamol depresses internuncial neurons and blocks spinal polysynaptic reflexes, preventing convulsions induced by electric shock while sparing direct muscle fiber contraction. In contrast to direct-acting relaxants like , which inhibit calcium release from the via binding to reduce excitation-contraction coupling in , methocarbamol lacks peripheral effects and targets CNS pathways exclusively.

Pharmacokinetics

Methocarbamol is rapidly and well absorbed from the after , with an typically occurring within 30 minutes and peak plasma concentrations reached in 1 to 2 hours. The drug exhibits high , estimated at approximately 80% to nearly complete absorption in humans. Food consumption delays the rate of absorption by about 30 minutes but does not alter the overall extent of . Upon absorption, methocarbamol distributes widely throughout the body. It is moderately bound to plasma proteins, at levels of 46% to 50%, allowing for effective tissue penetration. The crosses the blood-brain barrier, as demonstrated in , which supports its central nervous system-mediated effects. The elimination of methocarbamol in plasma is 1 to 2 hours, reflecting its relatively rapid clearance. With repeated dosing every 6 hours, steady-state plasma concentrations are generally achieved within 4 to 6 hours. Differences in across administration routes include immediate peak plasma levels following intravenous infusion, whereas results in a slightly delayed onset and peak compared to the oral route, though both parenteral forms provide faster systemic exposure than oral dosing.

Metabolism and excretion

Methocarbamol is primarily metabolized in the liver through dealkylation and pathways, followed by conjugation via or sulfation. The main metabolites include 3-(2-hydroxyphenoxy)-1,2-propanediol-1- (formed via demethylation) and 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1- (formed via hydroxylation on the aromatic ring); these are inactive and structurally similar to guaifenesin but retain the carbamate moiety, as the carbamate bond is not hydrolyzed. No major active metabolites are produced. Excretion occurs predominantly via the kidneys, with the majority of the dose eliminated in the as conjugated metabolites and approximately 10-15% as unchanged following a single oral dose. Fecal excretion is minimal, accounting for less than 5% of the dose in humans. There is no significant enterohepatic recirculation, as evidenced by the low fecal output. In patients with hepatic impairment, the of methocarbamol may be extended due to its reliance on liver-mediated dealkylation, though specific quantitative data are limited. This metabolism contributes to the drug's relatively short overall in .

Chemistry

Chemical structure and properties

Methocarbamol has the molecular formula C11H15NO5 and a molecular weight of 241.24 g/mol. Its IUPAC name is 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate. The chemical structure consists of a ester derived from a backbone, where one primary hydroxyl group is esterified with and the other is etherified with 2-methoxyphenol (). Methocarbamol possesses a chiral center at the 2-position and is utilized as a . Methocarbamol appears as a white powder. It is sparingly soluble in (approximately 2.5 g/100 mL at 20°C) and in , soluble in alcohol (with heating) and , and insoluble in and n-hexane. The compound exhibits an acidic pKa of approximately 13.1, corresponding to the hydroxyl group. Methocarbamol is stable at , with solutions (e.g., 4 mg/mL in or 5% dextrose) remaining stable for up to 6 days when stored without to prevent precipitation or haze.

Synthesis

Methocarbamol is primarily synthesized through a two-step process beginning with the reaction of and in the presence of a basic catalyst, such as , to form 2,3-epoxypropyl 2-methoxyphenyl (glycidyl guaiacol ). This nucleophilic ring-opening of by the phenoxide ion of proceeds under conditions in an excess of , yielding the intermediate with high efficiency. The is then reacted with CO₂ under (4000-10000 hPa at 110-160°C) in the presence of a catalyst to form a cyclic intermediate, which is subsequently treated with to yield methocarbamol. An alternative synthetic route starts from and 3-chloro-1,2-propanediol ( α-monochlorohydrin) to produce 3-(2-methoxyphenoxy)-1,2-propanediol (guaifenesin) via using the sodium salt of guaiacol. The diol is then selectively converted at the primary hydroxyl to the by reaction with to form the chlorocarbonate intermediate, followed by treatment with . The industrial process, established in the 1950s through patented methods, typically employs the route or variations of the pathway, achieving product purity greater than 90% after recrystallization and no stereochemical resolution is required, as the product is a of the chiral molecule. Key precursors include , derived from lignin via of , and or derivatives. Modern variants focus on greener approaches to improve efficiency and reduce waste in the synthesis of intermediates.

History

Development

Methocarbamol was developed in the mid-1950s by the A. H. Robins Company (later acquired by ) through a screening program of compounds designed to identify novel centrally acting relaxants. The compound emerged as a guaiacol glyceryl ether derivative, synthesized to address the need for effective muscle relief with reduced side effects compared to existing agents. Preclinical research in the early to mid-1950s focused on models to evaluate its efficacy and safety profile. Initial studies demonstrated that methocarbamol provided marked protection against strychnine-induced convulsions and death in rats, cats, and dogs, effectively reducing spasms while avoiding curare-like muscle paralysis or significant interference with respiration. These findings highlighted its selective depressant action on hyperactivity without profound generalized . The development of methocarbamol was driven by the search for a non-barbiturate alternative to agents like , which had been introduced in as an but exhibited properties with concerns over abuse potential and overdose risks. By modifying structures related to (an early precursor to ), researchers aimed for a compound offering safer CNS modulation specifically for musculoskeletal conditions. Early lab-scale synthesis during this phase confirmed its stability and solubility, supporting further testing. Following successful preclinical outcomes, including confirmation of central effects in animal models, the compound transitioned to human trials in 1956, with initial evaluations targeting acute injury and spasm scenarios to assess tolerability and therapeutic potential.

Regulatory approval

Methocarbamol was approved by the U.S. (FDA) on July 16, 1957, under the brand name Robaxin for oral and intravenous administration as an adjunct to rest, , and other measures to relieve discomfort from acute, painful musculoskeletal conditions. The approval encompassed both tablet and injectable formulations, marking its initial market entry for relaxation. The drug's indications were later supported by clinical evidence for use as an adjunct in managing neuromuscular manifestations of , with the injectable form recommended for this purpose based on established efficacy in controlling spasms. Generic versions of methocarbamol tablets and injections received FDA approval prior to January 1, 1982, broadening access beyond the branded product. In July 2025, the FDA approved an oral suspension formulation of methocarbamol (NDA 219843). Internationally, methocarbamol has been authorized in various European countries since the late through national regulatory bodies, prior to the establishment of centralized (EMA) procedures; for instance, oral formulations are approved in for musculoskeletal disorders. It is not included on the World Health Organization's Model List of . Post-marketing surveillance led to label revisions for the injectable form, with updates in September 2023 and June 2024 emphasizing warnings for intravenous administration, including a maximum injection rate of 3 mL per minute, avoidance of , and a total daily dosage limit of 30 mL (three vials) for no more than three consecutive days except in cases, to mitigate risks such as syncope and . As of 2025, no warnings have been issued for methocarbamol. Pediatric use is restricted, with safety and effectiveness not established for individuals under 16 years old except as an adjunct for , where dosing starts at 15 mg/kg or 500 mg/m² intravenously, not exceeding 1.8 g/m² for three consecutive days.

Society and culture

Brand names and marketing

Methocarbamol was first introduced to the market under the brand name Robaxin by the A.H. Robins Company, which was later acquired by American Home Products (now part of via ), following FDA approval in 1957. The drug was promoted as an adjunct for acute musculoskeletal conditions, often in combination with rest and . A notable combination product, Robaxisal, pairs methocarbamol with aspirin to address both muscle spasms and associated pain, and has been available primarily in and other international markets. Internationally, methocarbamol is marketed under various brand names, including Metoflex in , Delaxin and Miolaxin in several countries, and Robaxin in regions like the . With the expiration of the original U.S. in the mid-1970s—stemming from a 1956 issuance to A.H. Robins—the market has seen widespread generic production, with over 50 generic formulations distributed globally by numerous manufacturers. Early marketing in the and highlighted Robaxin as a non-addictive alternative to other muscle relaxants, targeting physicians through print advertisements in medical journals that emphasized its effects without narcotic potential. By the 2000s, promotional efforts shifted toward combination therapies for conditions like , as seen in campaigns for products like Robaxacet (methocarbamol with acetaminophen), which featured television commercials portraying relief from everyday muscle strains. remains limited due to its prescription status, though recent physician-targeted materials underscore its short-term safety profile for acute use.

Availability and economics

Methocarbamol is available by prescription only in most countries for human use, including the , where it is indicated for short-term relief of acute musculoskeletal conditions. In , it is commonly prescribed for dogs, cats, and horses to manage muscle spasms associated with trauma or , though it requires a veterinary prescription and is not available over-the-counter. In the , it ranked as the 121st most commonly prescribed medication in 2023, with approximately 5.3 million prescriptions dispensed. Generic methocarbamol tablets, the primary form available, cost between $0.10 and $0.20 per 500 mg tablet as of 2025, making it an affordable option for patients. Intravenous formulations, used for more severe cases, are priced at approximately $7.50 to $10 per 10 mL dose (1,000 mg) under standard schedules. These low costs position methocarbamol as a budget-friendly alternative to branded muscle relaxants like or . Most U.S. insurance plans, including and commercial formularies, cover methocarbamol at Tier 1 or Tier 2 levels, resulting in low copayments of $5 to $20 for a 30-day supply. This coverage, combined with its generic status since the , enhances accessibility and contributes to its role as a cost-effective first-line in managing muscle spasms. Globally, methocarbamol is widely accessible through generic manufacturers, particularly in low- and middle-income countries where affordable versions support treatment of musculoskeletal disorders, though it is not included on the World Health Organization's Model List of Essential Medicines. Supply shortages, which affected tablet availability around 2020 due to constraints, have been resolved, with multiple suppliers ensuring steady distribution as of 2025. In the U.S. skeletal muscle relaxants market, methocarbamol holds an estimated 4-5% share of prescriptions, driven primarily by its low cost and established profile relative to other agents.

Research directions

Clinical studies

Methocarbamol's as a relaxant was initially established through pivotal randomized controlled trials (RCTs) in the 1950s, which demonstrated its superiority over in treating acute muscle spasms associated with musculoskeletal conditions. Early clinical trials in the 1950s, including a 1958 study, demonstrated methocarbamol's over in treating acute muscle spasms, supporting its approval for short-term use. A 2021 systematic review and of muscle relaxants for non-specific , including data on methocarbamol, found very low certainty evidence of small pain reductions (mean difference -7.7 points on a 0-100 scale) with non-benzodiazepine antispasmodics including methocarbamol, not reaching (threshold ≥10 points). The analysis, drawing from 49 RCTs involving over 6,500 participants, highlighted methocarbamol's role among non-benzodiazepine antispasmodics, though evidence quality was very low due to heterogeneity and risk of bias in older studies. No high-quality data supports long-term efficacy beyond two weeks, with recommendations limited to adjunctive short-term use alongside analgesics or . In management, methocarbamol has been evaluated historically as an adjunctive therapy to control neuromuscular spasms, though benzodiazepines are now preferred in modern protocols. Safety profiles from comparative trials suggest methocarbamol's favorable tolerability, with lower rates of compared to alternatives like . Common adverse events across trials include mild and , occurring in 10-20% of patients, with rare serious events like seizures. Despite these findings, significant evidence gaps persist, particularly in pediatric populations and non-Caucasian groups, where data are sparse and extrapolated from studies. Methocarbamol lacks dedicated pediatric RCTs, with and dosing inferred from limited case series showing no major differences but highlighting needs for age-specific trials. Intravenous administration provides rapid onset and is preferred in acute hospitalized settings, while oral formulations offer good . Non-Caucasian representation remains low (<20% in most trials), limiting generalizability to diverse ethnic groups.

Investigational uses

Methocarbamol has shown promise in investigational applications for beyond its standard musculoskeletal indications, particularly in cases. A of young adults with traumatic fractures demonstrated that incorporating methocarbamol into multimodal pain regimens reduced daily consumption by about 35%, from 337 mg to 219 mg oral equivalents, while also shortening hospital length of stay from 4 to 3 days without increasing adverse events. In fibromyalgia, methocarbamol is being explored as an adjunct for spasm modulation and relief, though evidence remains preliminary and mixed. A systematic review of long-term skeletal muscle relaxant use, including methocarbamol, analyzed multiple trials and found inconsistent benefits for fibromyalgia symptoms, with no clear superiority over in pain reduction or functional improvement across 11 studies involving 391 participants. Other exploratory uses include relief of ureteral stent-related colic and muscle cramps in cirrhotic patients. A 2024 prospective with 60 participants found methocarbamol (750 mg every 6 hours as needed) superior to in lowering overall pain scores (PROMIS p=0.04; VAS p=0.026) following placement. A completed (NCT02642874) evaluated methocarbamol for cirrhotic muscle cramps, building on its central mechanism. A retrospective study on IV methocarbamol post-spine highlighted its role in multimodal , though evidence remains inconclusive. Progress in these areas is constrained by methocarbamol's generic status, which limits commercial incentives and funding for advanced . As of , no Phase III trials for indications have been initiated, primarily due to insufficient market exclusivity to recoup development costs for off-patent drugs.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/011011Orig1s070s071lbl.pdf
  2. https://www.ncbi.nlm.nih.gov/books/NBK565868/
  3. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/219843Orig1s000ltr.pdf
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Methocarbamol
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11790slr046_robaxin_lbl.pdf
  6. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3448618-c9b4-4cb9-a30e-1afc8197cfe1
  7. https://www.acpjournals.org/doi/10.7326/M16-2367
  8. https://f1000research.com/articles/13-1139
  9. https://www.mayoclinic.org/drugs-supplements/methocarbamol-injection-route/description/drg-20071924
  10. https://www.drugs.com/dosage/methocarbamol.html
  11. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=090a3d3d-92c3-4c30-a648-436461f81702
  12. https://reference.medscape.com/drug/robaxin-methocarbamol-343343
  13. https://www.drugs.com/dosage/robaxin.html
  14. https://www.jpsmjournal.com/article/S0885-3924(04)00215-5/fulltext
  15. https://www.bmj.com/content/374/bmj.n1446
  16. https://www.ncbi.nlm.nih.gov/books/NBK526037/
  17. https://www.aafp.org/pubs/afp/issues/2008/0801/p365.html
  18. https://www.drugs.com/compare/carisoprodol-vs-methocarbamol
  19. https://www.osmosis.org/learn/Skeletal_muscle_relaxants:_Nursing_Pharmacology
  20. https://emj.bmj.com/content/41/9/574
  21. https://www.singlecare.com/blog/robaxin-vs-soma/
  22. https://www.drugs.com/disease-interactions/methocarbamol.html
  23. https://www.sciencedirect.com/topics/medicine-and-dentistry/methocarbamol
  24. https://www.mayoclinic.org/drugs-supplements/methocarbamol-oral-route/description/drg-20071962
  25. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
  26. https://www.drugs.com/monograph/methocarbamol.html
  27. https://pubmed.ncbi.nlm.nih.gov/23821610/
  28. https://www.uspharmacist.com/article/inappropriate-use-of-skeletal-muscle-relaxants-in-geriatric-patients
  29. https://pubmed.ncbi.nlm.nih.gov/7101197/
  30. https://www.ncbi.nlm.nih.gov/books/NBK618294/
  31. https://www.e-lactation.com/en/methocarbamol-pr/
  32. https://publications.aap.org/pediatriccare/drug-monograph/18/5734/Methocarbamol
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC5820149/
  34. https://www.ncbi.nlm.nih.gov/books/NBK548286/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC11413720/
  36. https://medlineplus.gov/druginfo/meds/a682579.html
  37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219843s000lbl.pdf
  38. https://www.drugs.com/sfx/methocarbamol-side-effects.html
  39. https://www.rxlist.com/robaxin-drug.htm
  40. https://www.drugs.com/methocarbamol.html
  41. https://go.drugbank.com/drugs/DB00423
  42. https://datasheets.scbt.com/sc-211809.pdf
  43. https://www.medcentral.com/drugs/monograph/8677-382579/methocarbamol-oral
  44. https://pdf.hres.ca/dpd_pm/00077592.PDF
  45. https://pubmed.ncbi.nlm.nih.gov/2253675/
  46. https://pubmed.ncbi.nlm.nih.gov/2703967/
  47. https://www.samhsa.gov/data/sites/default/files/reports/rpt56287/2024-nsduh-annual-national-report.pdf
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC9501796/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC11180590/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3092136/
  51. https://www.drugs.com/interactions-check.php?drug_list=1588-0%2C1615-0&professional=1
  52. https://www.drugs.com/drug-interactions/ibuprofen-with-methocarbamol-1310-0-1588-0.html
  53. https://www.goodrx.com/methocarbamol/interactions
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8420930/
  55. https://www.drugs.com/medical-answers/ardosons-called-3557096/
  56. https://pubmed.ncbi.nlm.nih.gov/14185803/
  57. https://www.drugs.com/drug-class/monoamine-oxidase-inhibitors.html
  58. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/methocarbamol
  59. https://go.drugbank.com/drugs/DB01219
  60. https://pdf.hres.ca/dpd_pm/00018784.PDF
  61. https://pdf.hres.ca/dpd_pm/00020441.PDF
  62. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f0d3966-962d-fa7c-e053-2a91aa0a8e3c
  63. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3148129.htm
  64. https://patents.google.com/patent/GB2216520A/en
  65. https://patents.google.com/patent/US2770649A/en
  66. https://www.sciencedirect.com/science/article/pii/S109671761730397X
  67. https://www.sciencedirect.com/science/article/pii/S2666086521001983
  68. https://www.zoetisus.com/content/_assets/docs/vmips/package-inserts/robaxin-v_injectable.pdf
  69. https://www.scirp.org/journal/paperinformation?paperid=72155
  70. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc16295e-f3aa-4ed5-9fd6-ac4c750e0bba
  71. https://clincalc.com/DrugStats/Drugs/Methocarbamol
  72. https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-notification_en.pdf
  73. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
  74. https://www.drugs.com/mtm/aspirin-and-methocarbamol.html
  75. https://search.library.wisc.edu/digital/ADPCUQX6NNM3Q48C
  76. https://www.youtube.com/watch?v=MSZ-N3XizuI
  77. https://www.drugs.com/robaxin.html
  78. https://www.chewy.com/methocarbamol-generic-tablets-dogs/dp/173632
  79. https://clincalc.com/DrugStats/Top300Drugs.aspx
  80. https://www.goodrx.com/methocarbamol
  81. https://www.horizonblue.com/providers/news/news-legal-notices/injectable-medication-specialty-pharmacy-fee-schedule-update-january-2025
  82. https://www.singlecare.com/blog/methocarbamol-without-insurance/
  83. https://www.goodrx.com/robaxin/medicare-coverage
  84. https://formularysearch.caremark.com/formularypdf/TuftsByTier_3.pdf
  85. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
  86. https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=423
  87. https://www.drugpatentwatch.com/p/drug-price/drugname/METHOCARBAMOL
  88. https://pubmed.ncbi.nlm.nih.gov/13538685/
  89. https://pubmed.ncbi.nlm.nih.gov/33045839/
  90. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823750
  91. https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-endourology-and-stone-disease/151770-aua-2024-comparing-methocarbamol-to-oxybutynin-for-stent-colic-a-prospective-randomized-controlled-trial.html
  92. https://clinicaltrials.gov/study/NCT02642874
  93. https://pubmed.ncbi.nlm.nih.gov/30444744/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC12602086/
  95. https://fas.org/publication/clearing-the-path-for-new-uses-for-generic-drugs/
Add your contribution
Related Hubs
User Avatar
No comments yet.